C

Can-Fite BioPharma Ltd

CANF

3.03300
USD
-0.193
(-5.98%)
مغلق
حجم التداول
832
الربح لكل سهم
0
العائد الربحي
0
P/E
-1
حجم السوق
16,948,070
أصول ذات صلة
A
AIM
-0.01500
(-4.18%)
0.34400 USD
A
AXSM
-1.255
(-1.44%)
86.075 USD
B
BLCM
-0.01620
(-4.09%)
0.36000 USD
C
CRBP
-0.500
(-0.84%)
59.160 USD
C
CYAD
0.00000
(0.00%)
0.93000 USD
F
FATE
-0.46000
(-8.61%)
4.88000 USD
I
IMUX
-0.02000
(-1.41%)
1.40000 USD
M
MACK
0
(0%)
0.000000 USD
M
MGNX
0.23500
(6.28%)
3.98000 USD
P
PRVB
-0.075
(-0.31%)
23.870 USD
V
VTVT
0.010
(0.07%)
14.540 USD
الأخبار المقالات

العنوان: Can/Fite BioPharma Ltd

القطاع: Healthcare
الصناعة: Biotechnology
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed intoa Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).